E
Understanding how PD-1 and PD-L1 immunotherapy works.

ASCO 2013 Highlights PD-1 and PD-L1 immunotherapy

Update on progress with PD-1 and PD-L1 immunotherapies at ASCO 2013.

May 16, 2013
E
ASCO 2013 Pharma Strategy Blog Video

ASCO 2013 Highlights Part 2

Access the ASCO 2013 Video Highlights Preview

May 28, 2013
E
ASCO 2013 Dr Susan O'Brien

Exciting times in CLL: an ASCO 2013 interview with Dr Susan O’Brien

Video interview at ASCO 2013 with Dr Susan O'Brien, Ashbel Smith Professor in the Department of Leukemia at the University of Texas, MD Anderson Cancer Center in Houston, in which she discusses many of the exciting new targeted therapies that are set to change the treatment of chronic lymphocytic leukemia (CLL).

June 10, 2013
E
Idelalisib iNHL study 101-09

Update on iNHL and CLL – idelalisib, obinutuzumab and ibrutinib

Gilead announced they will file idelalisib in iNHL in 2nd half of 2014. Interim CLL data is also expected then.

July 26, 2013